The GI Alliance (GIA), has announced a strategic partnership with Iterative Health, that aims to expand access to clinical trials across community-based practices.
By integrating GIA’s established clinical research sites with the Iterative Health Site Network, the partnership creates a global research network focused on gastrointestinal and hepatological diseases.
“This partnership represents a powerful step forward in our mission to integrate research into everyday GI care,” said Dr. Casey Chapman, chief medical officer of GI Alliance. “By combining GIA’s clinical depth with Iterative Health’s innovative infrastructure, we are enabling more physicians and their patients to participate in cutting-edge clinical trials without leaving their communities. This is how we bring the future of GI medicine directly to the frontlines of care.”
With the addition of 21 active GIA research sites—currently conducting over 80 Phase II–IV trials across various GI and hepatology indications—the Iterative Health Site Network now extends to more than 70 locations in the US and Europe. Iterative Health will lead trial management across current and future research sites, providing an operational infrastructure and supplying a pipeline of clinical trials.
“We are excited to partner with GIA to build a differentiated offering in clinical research across the United States. This reflects the reality of a shifting care paradigm, where the majority of care for even complex chronic diseases like inflammatory bowel disease and MASH are treated primarily within community practices,” said Jonathan Ng, founder and chief executive officer of Iterative Health. “Through this partnership, we will be able to enable physicians who are attracted to both research and community practice to find a home at GIA, providing the best possible infrastructure to lead the development of GI-focused therapeutics.”